title: Erythropoiesis-stimulating agents in renal medicine.
abstract: The four currently available erythropoiesis-stimulating agents (ESAs), the main drugs for correcting anemia in patients with chronic kidney disease (CKD), are epoetin alfa, epoetin beta, darbepoetin alfa, and continuous erythropoietin receptor activator. The last two have much longer half-lives, which means they can be administered less frequently. The expiry of the patents for epoetin alfa and epoetin beta some years ago opened up the way for the production of a number of biosimilars that are now marketed in the European Union. Because biosimilars cannot be identical to their originator, a complex and still-evolving regulatory policy has been generated, but there are still a number of issues concerning international naming, automatic substitution, and safety. All ESAs are effective in correcting renal anemia and increasing hemoglobin levels, but the choice of which to use should also take into account their pharmacokinetics and pharmacodynamics, their administration route, and economic issues. Following the publication of a number of trials indicating no benefit (and even possible harm) when ESAs are used to aim at near-normal hemoglobin levels in CKD patients, the hemoglobin target has become a major subject of discussion. According to the position statement of the Anemia Group of the European Renal Best Practice, it should generally be about 11-12 g/dL; however, a risk-benefit evaluation is warranted in individual patients, and high ESA doses driven by hyporesponsiveness should be avoided.
authors.affiliation: Department of Nephrology, Dialysis and Renal Transplant, Ospedale A. Manzoni, Via dell'Eremo 9, 23900 Lecco, Italy. nefrologia@spedale.lecco.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Locatelli
authors.forename: Lucia
authors.initials: L
authors.lastname: Del Vecchio
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease / Q000188:drug therapy; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000031:analogs & derivatives / Q000096:biosynthesis / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D005062:European Union; D006397:Hematinics / Q000191:economics / Q000493:pharmacokinetics* / Q000494:pharmacology*; D006454:Hemoglobins / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000493:pharmacokinetics / Q000494:pharmacology; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; C508420:continuous erythropoietin receptor activator; C103998:epoetin beta; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D011092:Polyethylene Glycols; D000068817:Epoetin Alfa